3rd Quarter - Report

FERRING PHARMACEUTICALS, INC. for FERRING PHARMACEUTICALS, INC.

Period 3rd Quarter 2025 Filed Oct 16, 2025 Signed by Moni Kehinde

Official filing
Firm
FERRING PHARMACEUTICALS, INC.
Client
FERRING PHARMACEUTICALS, INC.
Income
—
Expenses
$160,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to fertility treatment and coverage (no bill); issues related to federal employee health care coverage (Family Building FEHB Fairness Act, H.R. 1670 / S. 797), issues related to veterans health coverage (Veterans Infertility Treatment Act, H.R. 220 / no Senate bill), issues related to infertility coverage for members of the military included in the National Defense Authorization Act (S. 2296, Sec. 705 / H.R. 3838, Sec. 703).

LobbyistCovered position, as disclosed
TEGAN GELFAND —

Contacted: White House Office; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2296 (119th), S. 797 (119th), H.R. 220 (119th), H.R. 1670 (119th), H.R. 3838 (119th)

Taxation/Internal Revenue Code TAX

Issues related to establishing a tax credit for fertility treatments (IVF Access and Affordability Act, H.R. 1878 / no Senate bill; Infertility Treatment Affordability Act, H.R.4639 / no Senate bill).

LobbyistCovered position, as disclosed
TEGAN GELFAND —

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 4639 (119th), H.R. 1878 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.